Merck & Co., Inc. $MRK Stock: Investment Partners LTD. Grows Position

Investment Partners LTD. grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 72.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,813 shares of the company’s stock after buying an additional 3,715 shares during the quarter. Investment Partners LTD.’s holdings in Merck & Co., Inc. were worth $1,281,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after purchasing an additional 1,073,507 shares during the period. State Street Corp lifted its holdings in Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after acquiring an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Bank of America Corp DE raised its stake in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after buying an additional 2,919,780 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Merck & Co., Inc. by 23.8% in the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after acquiring an additional 2,969,856 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Richard R. Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares in the company, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Price Performance

MRK stock opened at $149.75 on Friday. The firm has a market cap of $369.46 billion, a P/E ratio of 154.38, a P/E/G ratio of 6.52 and a beta of 0.21. The firm’s fifty day moving average is $146.90 and its 200 day moving average is $126.69. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The company had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Research analysts predict that Merck & Co., Inc. will post 2.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MRK. Argus increased their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. HSBC increased their price objective on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Morgan Stanley cut their price objective on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Leerink Partners lifted their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Finally, Rothschild & Co Redburn increased their target price on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Seventeen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.08.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.